Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-312025-12-312025-01-01truefalseNo description of principal activity44trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 13714637 2025-01-01 2025-12-31 13714637 2024-01-01 2024-12-31 13714637 2025-12-31 13714637 2024-12-31 13714637 c:Director4 2025-01-01 2025-12-31 13714637 d:CurrentFinancialInstruments 2025-12-31 13714637 d:CurrentFinancialInstruments 2024-12-31 13714637 d:Non-currentFinancialInstruments 2025-12-31 13714637 d:Non-currentFinancialInstruments 2024-12-31 13714637 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 13714637 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 13714637 d:Non-currentFinancialInstruments d:AfterOneYear 2025-12-31 13714637 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 13714637 d:ShareCapital 2025-12-31 13714637 d:ShareCapital 2024-12-31 13714637 d:SharePremium 2025-12-31 13714637 d:SharePremium 2024-12-31 13714637 d:RetainedEarningsAccumulatedLosses 2025-12-31 13714637 d:RetainedEarningsAccumulatedLosses 2024-12-31 13714637 c:OrdinaryShareClass1 2025-01-01 2025-12-31 13714637 c:OrdinaryShareClass1 2025-12-31 13714637 c:OrdinaryShareClass1 2024-12-31 13714637 c:OrdinaryShareClass2 2025-01-01 2025-12-31 13714637 c:OrdinaryShareClass2 2025-12-31 13714637 c:OrdinaryShareClass2 2024-12-31 13714637 c:OrdinaryShareClass3 2025-01-01 2025-12-31 13714637 c:OrdinaryShareClass3 2025-12-31 13714637 c:OrdinaryShareClass3 2024-12-31 13714637 c:OrdinaryShareClass4 2025-01-01 2025-12-31 13714637 c:OrdinaryShareClass4 2025-12-31 13714637 c:OrdinaryShareClass4 2024-12-31 13714637 c:FRS102 2025-01-01 2025-12-31 13714637 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 13714637 c:FullAccounts 2025-01-01 2025-12-31 13714637 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 13714637 6 2025-01-01 2025-12-31 13714637 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 13714637









DERMMA HOLDINGS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025

 
DERMMA HOLDINGS LIMITED
REGISTERED NUMBER: 13714637

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Investments
 4 
3,168,992
2,534,561

Current assets
  

Debtors
 5 
2
2,676

Cash at bank and in hand
 6 
350,852
1,369

  
350,854
4,045

Creditors: amounts falling due within one year
 7 
(368,362)
(283,558)

Net current liabilities
  
 
 
(17,508)
 
 
(279,513)

Total assets less current liabilities
  
3,151,484
2,255,048

Creditors: amounts falling due after more than one year
 8 
(280,000)
(140,000)

  

Net assets
  
2,871,484
2,115,048


Capital and reserves
  

Called up share capital 
  
103
103

Share premium account
  
44,982
44,982

Profit and loss account
  
2,826,399
2,069,963

Total equity
  
2,871,484
2,115,048


Page 1

 
DERMMA HOLDINGS LIMITED
REGISTERED NUMBER: 13714637
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2025

The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


N A McDermott
Director

Date: 7 July 2026

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
DERMMA HOLDINGS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Dermma Holdings Limited is a private company limited by shares and registered in England and Wales. Its registered office address is 86-90 Paul Street, London, EC2A 4NE.
The financial statements are presented in Sterling (£), rounded to the nearest £1.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Exemption from preparing consolidated financial statements

The company, and the group headed by it, qualify as small as set out in section 383 of the Companies Act 2006 and the parent and group are considered eligible for the exemption to prepare consolidated accounts.

 
2.3

Going concern

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

 
2.4

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.


 
2.5

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 3

 
DERMMA HOLDINGS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Financial instruments

The company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially
Page 4

 
DERMMA HOLDINGS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)


2.9
Financial instruments (continued)

recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

  
2.10

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.


3.


Employees

The average monthly number of employees, including directors, during the year was 4 (2024 - 4).


4.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 January 2025
2,534,561


Additions
634,431



At 31 December 2025
3,168,992






Net book value



At 31 December 2025
3,168,992



At 31 December 2024
2,534,561

Page 5

 
DERMMA HOLDINGS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025


5.


Debtors

2025
2024
£
£

Amounts owed by group undertakings
-
2,674

Other debtors
2
2

2
2,676



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
350,852
1,369



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Amounts owed to group undertakings
9,700
9,700

Other creditors
354,582
269,778

Accruals and deferred income
4,080
4,080

368,362
283,558


There are fixed and floating charges over the assets of the company in respect of the amounts owed to other creditors.


8.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Debentures loans
280,000
140,000


There are fixed and floating charges over the assets of the company in respect of the amounts owed to other creditors.

Page 6

 
DERMMA HOLDINGS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

9.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



7,500 (2024 - 7,500) A Ordinary shares of £0.001 each
7.500
7.500
42,500 (2024 - 42,500) B Ordinary shares of £0.001 each
42.500
42.500
10,625 (2024 - 10,625) C Ordinary shares of £0.001 each
10.625
10.625
42,500 (2024 - 42,500) D Ordinary shares of £0.001 each
42.500
42.500

103.125

103.125



10.


Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

 
Page 7